← All trials
NCT05580159
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Dec 11, 2022
- Completion date
- May 11, 2023
- First posted
- Oct 14, 2022
- Last posted
- Oct 14, 2022
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stemirna TherapeuticsLead sponsor
- Government of CambodiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.